Abstract
Clinical evaluation of grepafloxacin in the treatment of various infectious diseases in the field of internal medicine. The clinical usefulness of grepafloxacin (GPFX), a new quinolone synthesized as an oral antibacterial agent, in various infections in the field of internal medicine was investigated by collaborative research at 62 institutions nationwide. GPFX was administered primarily to patients with respiratory tract infections (RTI), mostly at daily doses of 100~300 mg once or in 2 divided doses. Clinical efficacy was evaluated in 509 of a total of 525 patients for analysis and efficacy was observed in 443 (87.0%) of the 509, including 432 (87.1%) of 496 patients with RTI and 11 (84.6%) of 13 patients with urinary tract infections (UTI). In RTI by disease, clinical efficacy was observed in 19 (86.4%) of 22 patients with pharyngolaryngitis or pharyngitis, 17 (94.4%) of 18 with tonsillitis, 53 (91.4%) of 58 with acute bronchitis, 104 (87.4%) of 119 with pneumonia, 17 (89.5%) of 19 with mycoplasmal pneumonia, 5 (100%) of 5 with atypical pneumonia, 117 (87.3%) of 133 with chronic bronchitis, 48 of 63 with bronchiectasis, 17 (89.5%) of 19 with diffuse panbronchiolitis, and 35 (87.5%) of 40 with secondary infection with chronic respiratory disease. Bacteriological efficacy in RTI was evaluated in 233 patients. Bacteriological eradication was observed in 154 (78.2%) of 197 patients with monomicrobial infection and 22 (61.1%) of 36 with polymicrobial infection. For monomicrobial infection, bacteriological efficacy was higher in patients infected with gram-positive bacteria (48 of 53, 90.6%) than in patients infected with gram-negative bacteria (105 of 142, 73.9%). The MIC80 of GPFX was 0.39 μg/ml in 115 strains of causative organisms in which the MIC80 was determined in RTI, and the MIC80 of norfloxacin (NFLX), ofloxacin (0FLX), enoxacin (ENX) and ciprofloxacin (CPFX) were 6.25, 1.56, 6.25 and 0.78 μg/ml, respectively, in 97 strains. Adverse drug reactions were observed in 26 (5.0%, 38 cases) of 519 patients, including mostly gastrointestinal symptoms, CNS symptoms and hypersensitive symptoms. Abnormal clinical laboratory test values were observed in 49 (10.0%) of 490 patients. Major changes included increased eosinophil and transaminase. None of the reported symptoms or abnormal changes were serious. Based on clinical efficacy, adverse drug reactions and abnormal clinical laboratory test values, GPFX was judged to be useful in 432 (84.7%) of a total of 510 patients, 422 (84.9%) of 497 with RTI and 10 (76.9%) of 13 with UTI. From these results, GPFX was considered to be useful in the treatment of various infectious diseases, particularly RTI, in the field of internal medicine.
Original language | English |
---|---|
Pages (from-to) | 333-351 |
Number of pages | 19 |
Journal | Japanese Journal of Chemotherapy |
Volume | 43 |
DOIs | |
Publication status | Published - 1995 |
All Science Journal Classification (ASJC) codes
- Pharmacology
- Pharmacology (medical)
Access to Document
Other files and links
Fingerprint
Dive into the research topics of 'Clinical evaluation of grepafloxacin in the treatment of various infectious diseases in the field of internal medicine'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
Clinical evaluation of grepafloxacin in the treatment of various infectious diseases in the field of internal medicine. / Kobayashi, Hiroyuki; Takeda, Hiroaki; Watanabe, Hidehiro; Ohtami, Hiroshi; Sakayori, Susumu; Saito, Akira; Nakayama, Ichiro; Sato, Kiyoshi; Tomizawa, Masumi; Hiraga, Yohmei; Ohmichi, Mitsuhide; Takebe, Kazuo; Murakami, Seiichi; Masuda, Mitsuo; Imamura, Kenichi; Nakahata, Hisashi; Saito, Miyoko; Osonoi, Takeshi; Tamura, Masashi; Konishi, Kazuki; Obara, Kazuo; Chiba, Taro; Aoyama, Yoji; Shiba, Akiko; Watanabe, Akira; Niizuma, Kazunao; Takizawa, Shigeo; Nakai, Yushi; Honda, Yoshihiro; Katsu, Masataka; Ohishi, Akira; Nakamura, Morio; Kaneko, Kotaro; Sakauchi, Michihiro; Aosaki, Noboru; Shimada, Kaoru; Goto, Hajime; Goto, Mieko; Sano, Yasuyuki; Miyamoto, Yasufumi; Arai, Yasuo; Kikuchi, Norio; Sakai, Osamu; Shiba, Koya; Yoshida, Masaki; Hori, Seiji; Shimada, Jingoro; Shimizu, Kihachiro; Nakata, Koichiro; Nakatani, Tatsuo; Tsuboi, Eiyasu; Narui, Koji; Nakamori, Yoshitaka; Inagawa, Hiroko; Totsuka, Kyoichi; Shibata, Yusuke; Kikuchi, Ken; Hasegawa, Hiromi; Mori, Takeshi; Isonuma, Hiroshi; Takahashi, Mayumi; Ebe, Tsukasa; Inagaki, Masayoshi; Kunii, Otohiko; Guji, Atsuko; Ohyatsu, Isao; Ono, Yasuo; Miyashita, Taku; Nishiya, Hajime; Tokumura, Yasumasa; Sugiyama, Hajime; Yamaguchi, Morimichi; Aoki, Masumi; Haga, Toshiaki; Miyashita, Hideo; Ikeda, Yasuo; Kisaki, Masahiro; Mori, Shigehisa; Uchida, Hiroshi; Kobayashi, Yoshio; Kudo, Koichiro; Horiuchi, Tadashi; Shoji, Shunsuke; Kabe, Junzaburo; Shishido, Harumi; Nagai, Hideaki; Satoh, Koji; Kurashima, Atsuyuki; Miyake, Shuji; Kawakami, Kenji; Hayashi, Koji; Matumoto, Fumio; Imai, Takeo; Sakurai, Iwao; Yoshikawa, Koji; Takahashi, Takayuki; Morita, Masayuki; Odagiri, Shigeki; Suzuki, Kaneo; Takahashi, Hiroshi; Takahashi, Kenichi; Okubo, Takao; Ikeda, Hirotada; Kaneko, Tamotsu; Arakawa, Masaaki; Aoki, Nobuki; Sekine, Osamu; Suzuki, Yasutoshi; Uno, Katsuji; Yagi, Motohiro; Takeda, Hajimu; Izumi, Saburo; Sato, Atsuhiko; Senda, Kingo; Suda, Takafumi; Tamura, Ryoji; Yoshitomi, Atsushi; Yagi, Takeshi; Takeuchi, Toshihiko; Yamada, Yasuo; Nakamura, Atsushi; Yamamoto, Toshinobu; Yamamoto, Kazuhide; Hanaki, Hidekazu; Yamamoto, Toshiyuki; Matsuura, Toru; Yamagoshi, Masahiro; Suzuki, Kanzo; Shimokata, Kaoru; Ichiyama, Satoshi; Saito, Hidehiko; Sakai, Shuzo; Nomura, Shiro; Senda, Kazuyoshi; Iwahara, Takeshi; Minami, Hironobu; Yamamoto, Masashi; Saito, Hiroshi; Yamori, Sadaaki; Shibagaki, Tomohisa; Nishiwaki, Keisuke; Nakanishi, Kazuo; Narita, Nobuhiro; Mikasa, Keiichi; Sawaki, Masayoshi; Konishi, Mitsuru; Maeda, Koichi; Hamada, Kaoru; Takeuchi, Shoji; Sakamoto, Masahiro; Tsujimoto, Masayuki; Kunimatsu, Mikikazu; Kuze, Fumiyuki; Kawai, Mitsuru; Miki, Fumio; Ikuno, Yoshiyasu; Murata, Akihito; Sakamoto, Kazuo; Hiruma, Masato; Otani, Shinichiro; Hara, Yasushi; Nakayama, Koji; Tanaka, Satohiko; Hanatani, Akihisa; Yano, Saburo; Nakagawa, Masaru; Soejima, Rinzo; Okimoto, Niro; Moriya, Osamu; Niki, Yoshihito; Matsushima, Toshiharu; Kimura, Makoto; Kobashi, Yoshihiro; Adachi, Norifumi; Tanabe, Jun; Tano, Yoshihiko; Hara, Hiroki; Yamakido, Michio; Hasegawa, Kenji; Ogura, Tsuyoshi; Asada, Kanji; Namikawa, Osamu; Nishioka, Shinsuke; Azuma, Masahiko; Maeda, Mikie; Shirakami, Minoru; Niho, Yoshiyuki; Sawae, Yoshiro; Okada, Kaoru; Takaki, Koji; Shimono, Nobuyuki; Misumi, Hiroyasu; Eguchi, Katsuhiko; Oizumi, Kotaro; Tokunaga, Naoto; Ichikawa, Yoichiro; Yano, Takafumi; Hara, Kohei; Kohno, Shigeru; Koga, Hironobu; Kaku, Mitsuo; Tomono, Kazunori; Ito, Naomi; Watanabe, Koichi; Matsumoto, Keizo; Takasugi, Masakazu; Taguchi, Mikio; Oishi, Kazunori; Takahashi, Atsushi; Watanabe, Hiroshi; Omori, Akemi; Watanabe, Kiwao; Nagatake, Tsuyoshi; Tanaka, Hirofumi; Yamauchi, Soichiro; Ichimiya, Tomoku; Hirai, Kazufumi; Kawano, Hiroshi; Tashiro, Takayoshi; Shima, Kiyoshi; Takenaka, Shinobu; Saito, Atsushi; Fukuhara, Hiroshi; Irabu, Yuei; Inadome, Jun; Kusano, Nobuchika; Furugen, Yoshiko; Nakasone, Isamu; Taira, Shinko.
In: Japanese Journal of Chemotherapy, Vol. 43, 1995, p. 333-351.Research output: Contribution to journal › Article › peer-review
}
TY - JOUR
T1 - Clinical evaluation of grepafloxacin in the treatment of various infectious diseases in the field of internal medicine
AU - Kobayashi, Hiroyuki
AU - Takeda, Hiroaki
AU - Watanabe, Hidehiro
AU - Ohtami, Hiroshi
AU - Sakayori, Susumu
AU - Saito, Akira
AU - Nakayama, Ichiro
AU - Sato, Kiyoshi
AU - Tomizawa, Masumi
AU - Hiraga, Yohmei
AU - Ohmichi, Mitsuhide
AU - Takebe, Kazuo
AU - Murakami, Seiichi
AU - Masuda, Mitsuo
AU - Imamura, Kenichi
AU - Nakahata, Hisashi
AU - Saito, Miyoko
AU - Osonoi, Takeshi
AU - Tamura, Masashi
AU - Konishi, Kazuki
AU - Obara, Kazuo
AU - Chiba, Taro
AU - Aoyama, Yoji
AU - Shiba, Akiko
AU - Watanabe, Akira
AU - Niizuma, Kazunao
AU - Takizawa, Shigeo
AU - Nakai, Yushi
AU - Honda, Yoshihiro
AU - Katsu, Masataka
AU - Ohishi, Akira
AU - Nakamura, Morio
AU - Kaneko, Kotaro
AU - Sakauchi, Michihiro
AU - Aosaki, Noboru
AU - Shimada, Kaoru
AU - Goto, Hajime
AU - Goto, Mieko
AU - Sano, Yasuyuki
AU - Miyamoto, Yasufumi
AU - Arai, Yasuo
AU - Kikuchi, Norio
AU - Sakai, Osamu
AU - Shiba, Koya
AU - Yoshida, Masaki
AU - Hori, Seiji
AU - Shimada, Jingoro
AU - Shimizu, Kihachiro
AU - Nakata, Koichiro
AU - Nakatani, Tatsuo
AU - Tsuboi, Eiyasu
AU - Narui, Koji
AU - Nakamori, Yoshitaka
AU - Inagawa, Hiroko
AU - Totsuka, Kyoichi
AU - Shibata, Yusuke
AU - Kikuchi, Ken
AU - Hasegawa, Hiromi
AU - Mori, Takeshi
AU - Isonuma, Hiroshi
AU - Takahashi, Mayumi
AU - Ebe, Tsukasa
AU - Inagaki, Masayoshi
AU - Kunii, Otohiko
AU - Guji, Atsuko
AU - Ohyatsu, Isao
AU - Ono, Yasuo
AU - Miyashita, Taku
AU - Nishiya, Hajime
AU - Tokumura, Yasumasa
AU - Sugiyama, Hajime
AU - Yamaguchi, Morimichi
AU - Aoki, Masumi
AU - Haga, Toshiaki
AU - Miyashita, Hideo
AU - Ikeda, Yasuo
AU - Kisaki, Masahiro
AU - Mori, Shigehisa
AU - Uchida, Hiroshi
AU - Kobayashi, Yoshio
AU - Kudo, Koichiro
AU - Horiuchi, Tadashi
AU - Shoji, Shunsuke
AU - Kabe, Junzaburo
AU - Shishido, Harumi
AU - Nagai, Hideaki
AU - Satoh, Koji
AU - Kurashima, Atsuyuki
AU - Miyake, Shuji
AU - Kawakami, Kenji
AU - Hayashi, Koji
AU - Matumoto, Fumio
AU - Imai, Takeo
AU - Sakurai, Iwao
AU - Yoshikawa, Koji
AU - Takahashi, Takayuki
AU - Morita, Masayuki
AU - Odagiri, Shigeki
AU - Suzuki, Kaneo
AU - Takahashi, Hiroshi
AU - Takahashi, Kenichi
AU - Okubo, Takao
AU - Ikeda, Hirotada
AU - Kaneko, Tamotsu
AU - Arakawa, Masaaki
AU - Aoki, Nobuki
AU - Sekine, Osamu
AU - Suzuki, Yasutoshi
AU - Uno, Katsuji
AU - Yagi, Motohiro
AU - Takeda, Hajimu
AU - Izumi, Saburo
AU - Sato, Atsuhiko
AU - Senda, Kingo
AU - Suda, Takafumi
AU - Tamura, Ryoji
AU - Yoshitomi, Atsushi
AU - Yagi, Takeshi
AU - Takeuchi, Toshihiko
AU - Yamada, Yasuo
AU - Nakamura, Atsushi
AU - Yamamoto, Toshinobu
AU - Yamamoto, Kazuhide
AU - Hanaki, Hidekazu
AU - Yamamoto, Toshiyuki
AU - Matsuura, Toru
AU - Yamagoshi, Masahiro
AU - Suzuki, Kanzo
AU - Shimokata, Kaoru
AU - Ichiyama, Satoshi
AU - Saito, Hidehiko
AU - Sakai, Shuzo
AU - Nomura, Shiro
AU - Senda, Kazuyoshi
AU - Iwahara, Takeshi
AU - Minami, Hironobu
AU - Yamamoto, Masashi
AU - Saito, Hiroshi
AU - Yamori, Sadaaki
AU - Shibagaki, Tomohisa
AU - Nishiwaki, Keisuke
AU - Nakanishi, Kazuo
AU - Narita, Nobuhiro
AU - Mikasa, Keiichi
AU - Sawaki, Masayoshi
AU - Konishi, Mitsuru
AU - Maeda, Koichi
AU - Hamada, Kaoru
AU - Takeuchi, Shoji
AU - Sakamoto, Masahiro
AU - Tsujimoto, Masayuki
AU - Kunimatsu, Mikikazu
AU - Kuze, Fumiyuki
AU - Kawai, Mitsuru
AU - Miki, Fumio
AU - Ikuno, Yoshiyasu
AU - Murata, Akihito
AU - Sakamoto, Kazuo
AU - Hiruma, Masato
AU - Otani, Shinichiro
AU - Hara, Yasushi
AU - Nakayama, Koji
AU - Tanaka, Satohiko
AU - Hanatani, Akihisa
AU - Yano, Saburo
AU - Nakagawa, Masaru
AU - Soejima, Rinzo
AU - Okimoto, Niro
AU - Moriya, Osamu
AU - Niki, Yoshihito
AU - Matsushima, Toshiharu
AU - Kimura, Makoto
AU - Kobashi, Yoshihiro
AU - Adachi, Norifumi
AU - Tanabe, Jun
AU - Tano, Yoshihiko
AU - Hara, Hiroki
AU - Yamakido, Michio
AU - Hasegawa, Kenji
AU - Ogura, Tsuyoshi
AU - Asada, Kanji
AU - Namikawa, Osamu
AU - Nishioka, Shinsuke
AU - Azuma, Masahiko
AU - Maeda, Mikie
AU - Shirakami, Minoru
AU - Niho, Yoshiyuki
AU - Sawae, Yoshiro
AU - Okada, Kaoru
AU - Takaki, Koji
AU - Shimono, Nobuyuki
AU - Misumi, Hiroyasu
AU - Eguchi, Katsuhiko
AU - Oizumi, Kotaro
AU - Tokunaga, Naoto
AU - Ichikawa, Yoichiro
AU - Yano, Takafumi
AU - Hara, Kohei
AU - Kohno, Shigeru
AU - Koga, Hironobu
AU - Kaku, Mitsuo
AU - Tomono, Kazunori
AU - Ito, Naomi
AU - Watanabe, Koichi
AU - Matsumoto, Keizo
AU - Takasugi, Masakazu
AU - Taguchi, Mikio
AU - Oishi, Kazunori
AU - Takahashi, Atsushi
AU - Watanabe, Hiroshi
AU - Omori, Akemi
AU - Watanabe, Kiwao
AU - Nagatake, Tsuyoshi
AU - Tanaka, Hirofumi
AU - Yamauchi, Soichiro
AU - Ichimiya, Tomoku
AU - Hirai, Kazufumi
AU - Kawano, Hiroshi
AU - Tashiro, Takayoshi
AU - Shima, Kiyoshi
AU - Takenaka, Shinobu
AU - Saito, Atsushi
AU - Fukuhara, Hiroshi
AU - Irabu, Yuei
AU - Inadome, Jun
AU - Kusano, Nobuchika
AU - Furugen, Yoshiko
AU - Nakasone, Isamu
AU - Taira, Shinko
PY - 1995
Y1 - 1995
N2 - Clinical evaluation of grepafloxacin in the treatment of various infectious diseases in the field of internal medicine. The clinical usefulness of grepafloxacin (GPFX), a new quinolone synthesized as an oral antibacterial agent, in various infections in the field of internal medicine was investigated by collaborative research at 62 institutions nationwide. GPFX was administered primarily to patients with respiratory tract infections (RTI), mostly at daily doses of 100~300 mg once or in 2 divided doses. Clinical efficacy was evaluated in 509 of a total of 525 patients for analysis and efficacy was observed in 443 (87.0%) of the 509, including 432 (87.1%) of 496 patients with RTI and 11 (84.6%) of 13 patients with urinary tract infections (UTI). In RTI by disease, clinical efficacy was observed in 19 (86.4%) of 22 patients with pharyngolaryngitis or pharyngitis, 17 (94.4%) of 18 with tonsillitis, 53 (91.4%) of 58 with acute bronchitis, 104 (87.4%) of 119 with pneumonia, 17 (89.5%) of 19 with mycoplasmal pneumonia, 5 (100%) of 5 with atypical pneumonia, 117 (87.3%) of 133 with chronic bronchitis, 48 of 63 with bronchiectasis, 17 (89.5%) of 19 with diffuse panbronchiolitis, and 35 (87.5%) of 40 with secondary infection with chronic respiratory disease. Bacteriological efficacy in RTI was evaluated in 233 patients. Bacteriological eradication was observed in 154 (78.2%) of 197 patients with monomicrobial infection and 22 (61.1%) of 36 with polymicrobial infection. For monomicrobial infection, bacteriological efficacy was higher in patients infected with gram-positive bacteria (48 of 53, 90.6%) than in patients infected with gram-negative bacteria (105 of 142, 73.9%). The MIC80 of GPFX was 0.39 μg/ml in 115 strains of causative organisms in which the MIC80 was determined in RTI, and the MIC80 of norfloxacin (NFLX), ofloxacin (0FLX), enoxacin (ENX) and ciprofloxacin (CPFX) were 6.25, 1.56, 6.25 and 0.78 μg/ml, respectively, in 97 strains. Adverse drug reactions were observed in 26 (5.0%, 38 cases) of 519 patients, including mostly gastrointestinal symptoms, CNS symptoms and hypersensitive symptoms. Abnormal clinical laboratory test values were observed in 49 (10.0%) of 490 patients. Major changes included increased eosinophil and transaminase. None of the reported symptoms or abnormal changes were serious. Based on clinical efficacy, adverse drug reactions and abnormal clinical laboratory test values, GPFX was judged to be useful in 432 (84.7%) of a total of 510 patients, 422 (84.9%) of 497 with RTI and 10 (76.9%) of 13 with UTI. From these results, GPFX was considered to be useful in the treatment of various infectious diseases, particularly RTI, in the field of internal medicine.
AB - Clinical evaluation of grepafloxacin in the treatment of various infectious diseases in the field of internal medicine. The clinical usefulness of grepafloxacin (GPFX), a new quinolone synthesized as an oral antibacterial agent, in various infections in the field of internal medicine was investigated by collaborative research at 62 institutions nationwide. GPFX was administered primarily to patients with respiratory tract infections (RTI), mostly at daily doses of 100~300 mg once or in 2 divided doses. Clinical efficacy was evaluated in 509 of a total of 525 patients for analysis and efficacy was observed in 443 (87.0%) of the 509, including 432 (87.1%) of 496 patients with RTI and 11 (84.6%) of 13 patients with urinary tract infections (UTI). In RTI by disease, clinical efficacy was observed in 19 (86.4%) of 22 patients with pharyngolaryngitis or pharyngitis, 17 (94.4%) of 18 with tonsillitis, 53 (91.4%) of 58 with acute bronchitis, 104 (87.4%) of 119 with pneumonia, 17 (89.5%) of 19 with mycoplasmal pneumonia, 5 (100%) of 5 with atypical pneumonia, 117 (87.3%) of 133 with chronic bronchitis, 48 of 63 with bronchiectasis, 17 (89.5%) of 19 with diffuse panbronchiolitis, and 35 (87.5%) of 40 with secondary infection with chronic respiratory disease. Bacteriological efficacy in RTI was evaluated in 233 patients. Bacteriological eradication was observed in 154 (78.2%) of 197 patients with monomicrobial infection and 22 (61.1%) of 36 with polymicrobial infection. For monomicrobial infection, bacteriological efficacy was higher in patients infected with gram-positive bacteria (48 of 53, 90.6%) than in patients infected with gram-negative bacteria (105 of 142, 73.9%). The MIC80 of GPFX was 0.39 μg/ml in 115 strains of causative organisms in which the MIC80 was determined in RTI, and the MIC80 of norfloxacin (NFLX), ofloxacin (0FLX), enoxacin (ENX) and ciprofloxacin (CPFX) were 6.25, 1.56, 6.25 and 0.78 μg/ml, respectively, in 97 strains. Adverse drug reactions were observed in 26 (5.0%, 38 cases) of 519 patients, including mostly gastrointestinal symptoms, CNS symptoms and hypersensitive symptoms. Abnormal clinical laboratory test values were observed in 49 (10.0%) of 490 patients. Major changes included increased eosinophil and transaminase. None of the reported symptoms or abnormal changes were serious. Based on clinical efficacy, adverse drug reactions and abnormal clinical laboratory test values, GPFX was judged to be useful in 432 (84.7%) of a total of 510 patients, 422 (84.9%) of 497 with RTI and 10 (76.9%) of 13 with UTI. From these results, GPFX was considered to be useful in the treatment of various infectious diseases, particularly RTI, in the field of internal medicine.
UR - http://www.scopus.com/inward/record.url?scp=0029101342&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0029101342&partnerID=8YFLogxK
U2 - 10.11250/chemotherapy1995.43.Supplement1_333
DO - 10.11250/chemotherapy1995.43.Supplement1_333
M3 - Article
AN - SCOPUS:0029101342
VL - 43
SP - 333
EP - 351
JO - Japanese Journal of Chemotherapy
JF - Japanese Journal of Chemotherapy
SN - 1340-7007
ER -